New Head-to-Head Trial of Major Biologics Is an Eye-Opener for Crohn’s Disease Therapy

title

A head-to-head randomized controlled trial found similar remission rates for two leading biologic therapies for Crohn's disease: ustekinumab and adalimumab.

Learn More